A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - BeOne

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ask to Join

BeOne Study ID

BGB-16673-304

ClinicalTrials.gov ID

NCT06973187

EudraCT Number

2025-521654-41-00

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents